[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 52.200.130.163. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 232
Citations 0
Comment & Response
August 2016

Gene Expression Classifier Testing and the Surgical Decision-Making Process for Patients With Thyroid Nodules—Reply

Author Affiliations
  • 1Division of Head and Neck Endocrine Surgery, Department of Otolaryngology–Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland
  • 2Endocrine Surgery, Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland
 

Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Otolaryngol Head Neck Surg. 2016;142(8):807. doi:10.1001/jamaoto.2016.0515

In Reply Drs Kloos and Barth,1 employees and equity owners of Veracyte raise questions about the design and findings of our study examining the effect of Veracyte’s Afirma gene expression classifier (GEC) on the practice of 10 thyroid surgeons at an academic institution.2

×